# Apertura Gene Therapy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apertura-gene-therapy

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.aperturagtx.com
- Total disclosed funding: $67M
- Latest round: Series A (Apr 22, 2022)
- Investors on record: 1

## About

Based in New York, US, and founded in 2021 by Ben Deverma, Apertura Gene Therapy, LLC trading as Apertura operates as a biotechnology company that develops gene therapy drugs to treat intractable diseases. In April 2022, Apertura Gene Therapy, LLC raised USD 67 million in series A funding led by new investor Deerfield Management. As of June 2022, the company is led by its CEO Dave Greenwald.

Apertura Gene Therapy, LLC develops genetic medicines for treating intractable diseases by simultaneously engineering AAV capsids, genetic regulatory elements, and payloads to overcome limitations in cellular access, gene expression, pre-existing immunity, and manufacturability.

The company will use the series A funding to increase genetic drugs to be used for its platform technology and further operational aid to similarly toughen its potential to develop gene remedy discoveries.

## Funding rounds

- Series A, Apr 22, 2022, $67M — Deerfield Management

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A